Imaging evaluation following transarterial radioembolization with yttrium-90 microspheres downstaging hepatocellular carcinoma: the first case in China

[摘要] Hepatocellular carcinoma (HCC) is one of the mostmalignant tumors, the morbidity and mortality ofHCC ranked 6th and 3rd among all malignant tumors,respectively. Patients with HCC in Asia tend to have poorerliver function and present at a more advanced stage thanpatients in Western countries (1). Approximately 70–90%of patients with HCC in Asia are co-infected with thehepatitis B virus (HBV). The percentage of Chinese HCCpatients who have HBV infection is estimated to accountfor approximately 75–80% in China (2). Furthermore,Asian and Western countries have different stagingsystems, disease management practices, and prognoses forHCC. Transarterial radioembolization with yttrium-90microspheres (TARE-Y90) has been used to treat HCC inWestern countries for 20 years, and Chinese guidelines forHCC management also recommend yttrium-90 as a localtreatment (3). However, there are no studies on the use ofTARE-Y90 in China.

[学科分类] 外科医学